A study of congenital generalized lipodystrophy (CGL) caused by BSCL2 gene mutation
Received date: 2022-06-30
Revised date: 2022-09-12
Online published: 2022-09-26
Supported by
the National Key Research and Development Program(2018YFA0506904);the National Key Research and Development Program(2019YFA0802701);the National Natural Science Foundation of China(82170882);the National Natural Science Foundation of China(91854122)
Congenital generalized lipodystrophy (CGL) is an extremely rare genetic disease mainly characterized by absence of whole-body adipose tissue and metabolic dysfunctions such as insulin resistance, diabetes mellitus, hypertriglyceridemia, hepatic steatosis, and acanthosis nigricans. In this study, we reported a novel case of a young woman patient with CGL. The patient came to the hospital for early-onset lipodystrophy and diabetes. She was 19-year-old with a height of 160 cm, a weight of 46 kg, BMI of 17.9 kg/m2, and a serum leptin level of 0.14 μg/L. Genomic DNA was extracted from blood samples of the patient and her family members, including her mother, father and brother. Genetic analysis revealed compound heterozygous mutations of the BSCL2 gene (c.560A>G and c.565G>T) in the patient. Her father carried a heterozygous mutation (c.565G>T), and her mother carried a heterozygous mutation (c.560A>G) in the BSCL2 gene. The mutant p.Y187C plasmid was transfected into HEK293T cells. The protein expression of SEIPIN and its interaction with glycerol-3-phosphate acyltransferase (GPAT3) were observed to be reduced. In addition, based on primary cultured skin fibroblasts from the patient, SEIPIN protein was decreased, and lipid droplets were much smaller when fatty acid was stimulated compared with those observed from healthy subject controls. However, histone deacetylase inhibitors (HDACis) was found capable of rescuing SEIPIN protein in fibroblasts of the patient. In addition, we further summarized and discussed gene mutations of BSCL2 reported in the current literature. Collectively, these findings have expanded the clinical phenotype and pathogenic gene spectrum of CGL, which might help clinicians to achieve better management of lipodystrophy.
Key words： CGL; BSCL2/SEIPIN; fibroblast; HDACi; diabetes
Jingya Ye, Aijie Huang, Zhenzhen Fu, Yingyun Gong, Hongyuan Yang, Hongwen Zhou . A study of congenital generalized lipodystrophy (CGL) caused by BSCL2 gene mutation[J]. Hereditas(Beijing), 2022 , 44(10) : 926 -936 . DOI: 10.16288/j.yczz.22-222
| [1] | Agarwal AK, Garg A. Genetic disorders of adipose tissue development, differentiation, and death. Annu Rev Genomics Hum Genet, 2006, 7: 175-199. |
| [2] | Agarwal AK, Garg A. Genetic basis of lipodystrophies and management of metabolic complications. Annu Rev Med, 2006, 57: 297-311. |
| [3] | Fei WH, Du XM, Yang HY. Seipin, adipogenesis and lipid droplets. Trends Endocrinol Metab, 2011, 22(6): 204-210. |
| [4] | Haque WA, Shimomura I, Matsuzawa Y, Garg A. Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab, 2002, 87(5): 2395. |
| [5] | Farooqi IS, Keogh JM, Kamath S, Jones S, Gibson WT, Trussell R, Jebb SA, Lip GY, O’Rahilly S. Partial leptin deficiency and human adiposity. Nature, 2001, 414(6859): 34-35. |
| [6] | Pareja-Galeano H, Santos-Lozano A, Sanchis-Gomar F, Fiuza-Luces C, Garatachea N, Gálvez BG, Lucia A, Emanuele E. Circulating leptin and adiponectin concentrations in healthy exceptional longevity. Mech Ageing Dev, 2017, 162: 129-132. |
| [7] | Van Maldergem L, Magré J, Khallouf TE, Gedde-Dahl T, Delépine M, Trygstad O, Seemanova E, Stephenson T, Albott CS, Bonnici F, Panz VR, Medina JL, Bogalho P, Huet F, Savasta S, Verloes A, Robert JJ, Loret H, De Kerdanet M, Tubiana-Rufi N, Mégarbané A, Maassen J, Polak M, Lacombe D, Kahn CR, Silveira EL, D'Abronzo FH, Grigorescu F, Lathrop M, Capeau J, O'Rahilly S. Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy. J Med Genet, 2002, 39(10): 722-733. |
| [8] | Agarwal AK, Simha V, Oral EA, Moran SA, Gorden P, O'Rahilly S, Zaidi Z, Gurakan F, Arslanian SA, Klar A, Ricker A, White NH, Bindl L, Herbst K, Kennel K, Patel SB, Al-Gazali L, Garg A. Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy. J Clin Endocrinol Metab, 2003, 88(10): 4840-4847. |
| [9] | Agarwal AK, Garg A. Seipin: a mysterious protein. Trends Mol Med, 2004, 10(9): 440-444. |
| [10] | Jiang M, Gao MM, Wu CM, He H, Guo XJ, Zhou ZM, Yang HY, Xiao XH, Liu G, Sha JH. Lack of testicular seipin causes teratozoospermia syndrome in men. Proc Natl Acad Sci USA, 2014, 111(19): 7054-7059. |
| [11] | Magré J, Delépine M, Khallouf E, Gedde-Dahl T, Van Maldergem L, Sobel E, Papp J, Meier M, Mégarbané A, Bachy A, Verloes A, d'Abronzo FH, Seemanova E, Assan R, Baudic N, Bourut C, Czernichow P, Huet F, Grigorescu F, de Kerdanet M, Lacombe D, Labrune P, Lanza M, Loret H, Matsuda F, Navarro J, Nivelon-Chevalier A, Polak M, Robert JJ, Tric P, Tubiana-Rufi N, Vigouroux C, Weissenbach J, Savasta S, Maassen JA, Trygstad O, Bogalho P, Freitas P, Medina JL, Bonnicci F, Joffe BI, Loyson G, Panz VR, Raal FJ, O'Rahilly S, Stephenson T, Kahn CR, Lathrop M, Capeau J, BSCL Working Group. Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat Genet, 2001, 28(4): 365-370. |
| [12] | Szymanski KM, Binns D, Bartz R, Grishin NV, Li WP, Agarwal AK, Garg A, Anderson RGW, Goodman JM. The lipodystrophy protein seipin is found at endoplasmic reticulum lipid droplet junctions and is important for droplet morphology. Proc Natl Acad Sci USA, 2007, 104(52): 20890-20895. |
| [13] | Fei WH, Shui GH, Gaeta B, Du XM, Kuerschner L, Li P, Brown AJ, Wenk MR, Parton RG, Yang HY. Fld1p, a functional homologue of human seipin, regulates the size of lipid droplets in yeast. J Cell Biol, 2008, 180(3): 473-482. |
| [14] | Salo VT, Belevich I, Li SQ, Karhinen L, Vihinen H, Vigouroux C, Magré J, Thiele C, Hölttä-Vuori M, Jokitalo E, Ikonen E. Seipin regulates ER-lipid droplet contacts and cargo delivery. EMBO J, 2016, 35(24): 2699-2716. |
| [15] | Wang HJ, Becuwe M, Housden BE, Chitraju C, Porras AJ, Graham MM, Liu XN, Thiam AR, Savage DB, Agarwal AK, Garg A, Olarte MJ, Lin QQ, Fröhlich F, Hannibal- Bach HK, Upadhyayula S, Perrimon N, Kirchhausen T, Ejsing CS, Walther TC, Farese RV. Seipin is required for converting nascent to mature lipid droplets. eLife, 2016, 5: e16582. |
| [16] | BERARDINELLI W. An undiagnosed endocrinometabolic syndrome:report of 2 cases. J Clin Endocrinol Metab, 1954, 14(2): 193-204. |
| [17] | Magré J, Delépine M, Van Maldergem L, Robert JJ, Maassen JA, Meier M, Panz VR, Kim CA, Tubiana-Rufi N, Czernichow P, Seemanova E, Buchanan CR, Lacombe D, Vigouroux C, Lascols O, Kahn CR, Capeau J, Lathrop M. Prevalence of mutations in AGPAT2 among human lipodystrophies. Diabetes, 2003, 52(6): 1573-1578. |
| [18] | Cristancho AG, Lazar MA. Forming functional fat: a growing understanding of adipocyte differentiation. Nat Rev Mol Cell Biol, 2011, 12(11): 722-734. |
| [19] | Miranda DM, Wajchenberg BL, Calsolari MR, Aguiar MJ, Silva JMCL, Ribeiro MG, Fonseca C, Amaral D, Boson WL, Resende BA, De Marco L. Novel mutations of the BSCL2 and AGPAT2 genes in 10 families with Berardinelli-Seip congenital generalized lipodystrophy syndrome. Clin Endocrinol (Oxf), 2009, 71(4): 512-517. |
| [20] | Qin YY, Zhang X, Xiang LQ, Shan QW, Li SD, Yan J, Lin FQ. A new compound heterozygous mutation of BSCL2 in a chinese zhuang ethnic family with congenital generalized lipodystrophy. Diabetes Metab Syndr Obes, 2019, 12: 2583-2587. |
| [21] | Yang Y, Ma L, Sun JJ, Gong XH, Cai C, Hong WC. The neonatal onset diabetes mellitus of Chinese neonate with congenital generalized lipodystrophy 2:a case report. BMC Endocr Disord, 2022, 22(1): 83. |
| [22] | Wang MF, Cun ZK, Peng JC, Chen R, Li JW. Type2 congenital generalized lipodystrophy with a heterozygous missense NOTCH2 mutation. Eur J Clin Nutr, 2022, 76(7): 1041-1043. |
| [23] | Lu J, Chiang J, Iyer RR, Thompson E, Kaneski CR, Xu DS, Yang CZ, Chen M, Hodes RJ, Lonser RR, Brady RO, Zhuang ZP. Decreased glucocerebrosidase activity in Gaucher disease parallels quantitative enzyme loss due to abnormal interaction with TCP1 and c-Cbl. Proc Natl Acad Sci USA, 2010, 107(50): 21665-21670. |
| [24] | Pagac M, Cooper DE, Qi YF, Lukmantara IE, Mak HY, Wu ZY, Tian Y, Liu ZH, Lei M, Du XM, Ferguson C, Kotevski D, Sadowski P, Chen WQ, Boroda S, Harris TE, Liu G, Parton RG, Huang X, Coleman RA, Yang HY. SEIPIN regulates lipid droplet expansion and adipocyte development by modulating the activity of glycerol-3- phosphate acyltransferase. Cell Rep, 2016, 17(6): 1546-1559. |
| [25] | Pipalia NH, Cosner CC, Huang A, Chatterjee A, Bourbon P, Farley N, Helquist P, Wiest O, Maxfield FR. Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts. Proc Natl Acad Sci USA, 2011, 108(14): 5620-5625. |
| [26] | Munkacsi AB, Chen FW, Brinkman MA, Higaki K, Gutiérrez GD, Chaudhari J, Layer JV, Tong A, Bard M, Boone C, Ioannou YA, Sturley SL. An “exacerbate- reverse” strategy in yeast identifies histone deacetylase inhibition as a correction for cholesterol and sphingolipid transport defects in human Niemann-Pick type C disease. J Biol Chem, 2011, 286(27): 23842-23851. |
| [27] | Hutt DM, Herman D, Rodrigues APC, Noel S, Pilewski JM, Matteson J, Hoch B, Kellner W, Kelly JW, Schmidt A, Thomas PJ, Matsumura Y, Skach WR, Gentzsch M, Riordan JR, Sorscher EJ, Okiyoneda T, Yates JR, Lukacs GL, Frizzell RA, Manning G, Gottesfeld JM, Balch WE. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol, 2010, 6(1): 25-33. |
| [28] | Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, Görgün CZ, Hotamisligil GS. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science, 2006, 313(5790): 1137-1140. |
| [29] | Jin J, Cao LF, Zhao ZH, Shen SX, Kiess W, Zhi DJ, Ye R, Cheng RQ, Chen L, Yang Y, Luo FH. Novel BSCL2 gene mutation E189X in Chinese congenital generalized lipodystrophy child with early onset diabetes mellitus. Eur J Endocrinol, 2007, 157(6): 783-787. |
| [30] | Antuna-Puente B, Boutet E, Vigouroux C, Lascols O, Slama L, Caron-Debarle M, Khallouf E, Lévy-Marchal C, Capeau J, Bastard JP, Magré J. Higher adiponectin levels in patients with Berardinelli-Seip congenital lipodystrophy due to seipin as compared with 1-acylglycerol-3-phosphate- o-acyltransferase-2 deficiency. J Clin Endocrinol Metab, 2010, 95(3): 1463-1468. |
| [31] | Nishiyama A, Yagi M, Awano H, Okizuka Y, Maeda T, Yoshida S, Takeshima Y, Matsuo M. Two Japanese infants with congenital generalized lipodystrophy due to BSCL2 mutations. Pediatr Int, 2009, 51(6): 775-779. |
| [32] | Simha V, Garg A. Inherited lipodystrophies and hypertriglyceridemia. Curr Opin Lipidol, 2009, 20(4): 300-308. |
| [33] | Patni N, Garg A. Congenital generalized lipodystrophies— new insights into metabolic dysfunction. Nat Rev Endocrinol, 2015, 11(9): 522-534. |
| [34] | Musso C, Cochran E, Javor E, Young J, Depaoli AM, Gorden P. The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients. Metabolism, 2005, 54(2): 255-263. |
| [35] | Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, Gorden P, Garg A. Leptin-replacement therapy for lipodystrophy. N Engl J Med, 2002, 346(8): 570-578. |
| [36] | Mulligan K, Khatami H, Schwarz JM, Sakkas GK, DePaoli AM, Tai VW, Wen MJ, Lee GA, Grunfeld C, Schambelan M. The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia. J Clin Endocrinol Metab, 2009, 94(4): 1137-1144. |
| [37] | Simha V, Subramanyam L, Szczepaniak L, Quittner C, Adams-Huet B, Snell P, Garg A. Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety. J Clin Endocrinol Metab, 2012, 97(3): 785-792. |
| [38] | Scroggins BT, Robzyk K, Wang DX, Marcu MG, Tsutsumi S, Beebe K, Cotter RJ, Felts S, Toft D, Karnitz L, Rosen N, Neckers L. An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol Cell, 2007, 25(1): 151-159. |
| [39] | Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol, 2007, 25(1): 84-90. |
| [40] | Lu J, Yang CZ, Chen M, Ye DY, Lonser RR, Brady RO, Zhuang ZP. Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease. Proc Natl Acad Sci USA, 2011, 108(52): 21200-21205. |
| [41] | Pipalia NH, Subramanian K, Mao S, Ralph H, Hutt DM, Scott SM, Balch WE, Maxfield FR. Histone deacetylase inhibitors correct the cholesterol storage defect in most Niemann-Pick C1 mutant cells. J Lipid Res, 2017, 58(4): 695-708. |
| [42] | Ramalingam SS, Parise RA, Ramanathan RK, Lagattuta TF, Musguire LA, Stoller RG, Potter DM, Argiris AE, Zwiebel JA, Egorin MJ, Belani CP. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res, 2007, 13(12): 3605-3610. |
/
| 〈 |
|
〉 |
www.chinagene.cn
备案号：京ICP备09063187号
